Beijing Aosaikang Pharmaceutical Co.,Ltd. (002755.SZ) announced that its wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., recently received an acceptance notice from the National Medical Products Administration for the marketing authorization application of Maltol Iron Capsules as an overseas-produced drug. The active ingredient, ferric maltol, is a novel, chemically stable complex formed from iron and maltol. It features a unique absorption mechanism and offers superior iron supplementation compared to traditional oral iron therapies. Maltol Iron Capsules demonstrate outstanding efficacy in treating iron deficiency conditions that are clinically challenging, such as anemia in inflammatory bowel disease (IBD) and chronic kidney disease (CKD). The capsules also improve patient compliance and tolerance, provide high bioavailability, cause minimal gastrointestinal irritation, and carry a low risk of iron overload. This makes them an ideal alternative for patients who cannot tolerate or do not respond well to existing oral iron preparations.